Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
1.025
-0.365 (-26.26%)
Oct 26, 2026, 1:10 PM EDT - Market open
Aardvark Therapeutics Employees
Aardvark Therapeutics had 28 employees as of June 30, 2026. The number of employees decreased by 3 or 9.68% compared to the same quarter last year. That makes Aardvark Therapeutics the 37,315th largest employer in the world and 5,210th in the United States.
Employees
28
Change (1Y)
-3
Growth (1Y)
-9.68%
Revenue / Employee
n/a
Profits / Employee
-$2,496,036
Market Cap
22.43M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 28 | -3 | -9.68% | 28 | 0 |
| Mar 31, 2026 | 40 | 14 | 53.85% | 40 | 0 |
| Dec 31, 2025 | 40 | 18 | 81.82% | 40 | 0 |
| Sep 30, 2025 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2025 | 31 | 17 | 121.43% | 31 | 0 |
| Mar 31, 2025 | 26 | 12 | 85.71% | 26 | 0 |
| Dec 31, 2024 | 22 | - | - | 22 | 0 |
| Sep 30, 2024 | 18 | - | - | 17 | 1 |
| Jun 30, 2024 | 14 | - | - | 12 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Metagenomi Therapeutics | 113 |
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| IRulya Therapeutics | 38 |
| Filana Therapeutics | 20 |
| BriaCell Therapeutics | 16 |
| TransCode Therapeutics | 12 |
AARD News
- 6 hours ago - Aardvark Therapeutics price target lowered to $2 from $4 at H.C. Wainwright - TheFly
- 16 hours ago - Aardvark Therapeutics price target lowered to $1.50 from $4 at BofA - TheFly
- 3 days ago - Aardvark Therapeutics price target lowered to $2.50 from $6 at RBC Capital - TheFly
- 3 days ago - Aardvark Therapeutics Transcript: FDA announcement - Transcripts
- 3 days ago - Aardvark Therapeutics Press release: FDA announcement - Filings
- 3 days ago - Aardvark Therapeutics Slides: FDA announcement - Filings
- 3 days ago - Aardvark Therapeutics reports exploratory efficacy data from HERO trial - TheFly
- 3 days ago - Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials - GlobeNewsWire